Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abbott Laboratories : to Launch Trial to Determine Better Treatment Options for Patients with Atrial Fibrillation, Heart Failure

05/06/2021 | 12:02pm EDT


ę MT Newswires 2021
All news about ABBOTT LABORATORIES
06/11INSIDER TRENDS : Insider at Abbott Laboratories Tax Sale Continues 90-Day Sellin..
MT
06/11ABBOTT LABORATORIESá : Maintains Quarterly Dividend of $0.45 Per Share, Payable ..
MT
06/11ABBOTTá : Declares 390th Consecutive Quarterly Dividend
PR
06/07INSIDER TRENDS : Abbott Laboratories Insider Sale for Taxes Adds to 90-Day Selli..
MT
06/07INSIDER TRENDS : Insider at Abbott Laboratories Makes Tax Sale Extends 90-Day Se..
MT
06/07ABBOTT LABORATORIESá : and Walgreens Launch Pilot Program to Increase Access to ..
PU
06/04S&P 500 Posts 0.6% Weekly Increase as May Jobs Climb But Miss Expectations; E..
MT
06/04ABBOTT LABORATORIESá : Confirms capacity to support expanded use of heartmate 3 ..
AQ
06/03Abbott Labs Plans Restructuring Due to Changes in Covid-19 Testing Demand
DJ
06/03ABBOTT LABORATORIESá : R&D pipeline continues to be highly productive, with a st..
PU
More news
Financials (USD)
Sales 2021 39 425 M - -
Net income 2021 5 861 M - -
Net Debt 2021 9 307 M - -
P/E ratio 2021 33,7x
Yield 2021 1,54%
Capitalization 196 B 196 B -
EV / Sales 2021 5,21x
EV / Sales 2022 5,14x
Nbr of Employees 109 000
Free-Float 89,0%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 124,86 $
Last Close Price 110,33 $
Spread / Highest target 43,2%
Spread / Average Target 13,2%
Spread / Lowest Target -12,1%
EPS Revisions
Managers and Directors
NameTitle
Robert B. Ford President, CEO, Chief Operating Officer & Director
Robert Emmett Funck Chief Financial Officer & Executive Vice President
Miles D. White Executive Chairman
Roxanne Schuh Austin Independent Director
Glenn Fletcher Tilton Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES0.77%196 037
MEDTRONIC PLC5.20%165 794
BECTON, DICKINSON AND COMPANY-3.87%69 953
HOYA CORPORATION1.26%48 451
ALIGN TECHNOLOGY, INC.12.59%47 612
SARTORIUS STEDIM BIOTECH S.A.30.77%41 615